MX2013005294A - Composicion que comprende un agonista de receptor de serotonina y una dicetopiperazina para el tratamiento de migrañas. - Google Patents
Composicion que comprende un agonista de receptor de serotonina y una dicetopiperazina para el tratamiento de migrañas.Info
- Publication number
- MX2013005294A MX2013005294A MX2013005294A MX2013005294A MX2013005294A MX 2013005294 A MX2013005294 A MX 2013005294A MX 2013005294 A MX2013005294 A MX 2013005294A MX 2013005294 A MX2013005294 A MX 2013005294A MX 2013005294 A MX2013005294 A MX 2013005294A
- Authority
- MX
- Mexico
- Prior art keywords
- diketopiperazine
- composition
- receptor agonist
- serotonin receptor
- treating migraines
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se describe un método para el tratamiento de migrañas. El método utiliza un sistema de suministro rápido de fármaco, el cual evita la desactivación o degradación del agente activo, incluyendo moléculas pequeñas y péptidos que se administran a un paciente con la necesidad del tratamiento. En particular, el sistema de suministro de fármaco está diseñado para suministrar fármacos al la circulación pulmonar en una forma rápida y terapéuticamente efectiva.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41177510P | 2010-11-09 | 2010-11-09 | |
US41233910P | 2010-11-10 | 2010-11-10 | |
PCT/US2011/060057 WO2012064892A1 (en) | 2010-11-09 | 2011-11-09 | Composition comprising a serotonin receptor agonist and a diketopiperazine for treating migraines |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013005294A true MX2013005294A (es) | 2013-12-06 |
MX340112B MX340112B (es) | 2016-06-27 |
Family
ID=45048258
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013005294A MX340112B (es) | 2010-11-09 | 2011-11-09 | Composicion que comprende un agonista de receptor de serotonina y una dicetopiperazina para el tratamiento de migrañas. |
Country Status (10)
Country | Link |
---|---|
EP (2) | EP3536368A1 (es) |
JP (2) | JP6092113B2 (es) |
KR (1) | KR101931392B1 (es) |
CN (2) | CN107854454A (es) |
AU (1) | AU2011326529B2 (es) |
BR (1) | BR112013011549B1 (es) |
CA (1) | CA2817337C (es) |
ES (1) | ES2732818T3 (es) |
MX (1) | MX340112B (es) |
WO (1) | WO2012064892A1 (es) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
DE60318938T2 (de) | 2002-03-20 | 2009-01-22 | Mannkind Corp., Valencia | Inhalationsgerät |
EP1786784B1 (en) | 2004-08-20 | 2010-10-27 | MannKind Corporation | Catalysis of diketopiperazine synthesis |
CA2578175C (en) | 2004-08-23 | 2014-10-14 | Mannkind Corporation | Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery |
US7803404B2 (en) | 2005-09-14 | 2010-09-28 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces |
BRPI0707991B8 (pt) | 2006-02-22 | 2021-05-25 | Mannkind Corp | métodos de preparação de um medicamento em pó seco com uma propriedade farmacêutica melhorada, dito pó seco e uso de uma quantidade efetiva do pó seco |
EP2570147B1 (en) | 2008-06-13 | 2017-10-18 | MannKind Corporation | A dry powder inhaler and system for drug delivery |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
US9364619B2 (en) | 2008-06-20 | 2016-06-14 | Mannkind Corporation | Interactive apparatus and method for real-time profiling of inhalation efforts |
TWI614024B (zh) | 2008-08-11 | 2018-02-11 | 曼凱公司 | 超快起作用胰島素之用途 |
US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
PL2405963T3 (pl) | 2009-03-11 | 2014-04-30 | Mannkind Corp | Urządzenie, układ i sposób pomiaru oporu inhalatora |
KR20180079458A (ko) | 2009-06-12 | 2018-07-10 | 맨카인드 코포레이션 | 한정된 비표면적을 갖는 디케토피페라진 마이크로입자 |
EP2496295A1 (en) | 2009-11-03 | 2012-09-12 | MannKind Corporation | An apparatus and method for simulating inhalation efforts |
RU2531455C2 (ru) | 2010-06-21 | 2014-10-20 | Маннкайнд Корпорейшн | Системы и способы доставки сухих порошковых лекарств |
CN105667994B (zh) | 2011-04-01 | 2018-04-06 | 曼金德公司 | 用于药物药盒的泡罩包装 |
WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
AU2012328885B2 (en) | 2011-10-24 | 2017-08-31 | Mannkind Corporation | Methods and compositions for treating pain |
CN108057154B (zh) | 2012-07-12 | 2021-04-16 | 曼金德公司 | 干粉药物输送系统和方法 |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
US10159644B2 (en) | 2012-10-26 | 2018-12-25 | Mannkind Corporation | Inhalable vaccine compositions and methods |
BR112015014510A2 (pt) | 2012-12-21 | 2017-11-21 | Sanofi Sa | agonistas de glp1/gip duais ou de glp1/gip/glucagon trigonais |
CA2906817C (en) | 2013-03-15 | 2022-01-18 | Mannkind Corporation | Microcrystalline diketopiperazine compositions and methods |
US9925144B2 (en) | 2013-07-18 | 2018-03-27 | Mannkind Corporation | Heat-stable dry powder pharmaceutical compositions and methods |
JP2016530930A (ja) | 2013-08-05 | 2016-10-06 | マンカインド コーポレイション | 通気装置及び方法 |
CN103599155B (zh) * | 2013-11-27 | 2015-12-02 | 广州安健实业发展有限公司 | 治疗偏头痛的方法 |
WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重glp-1/gip受體促效劑的艾塞那肽-4(exendin-4)胜肽類似物 |
EP3080149A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Dual glp-1/glucagon receptor agonists |
WO2015086729A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/gip receptor agonists |
US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
WO2016179026A1 (en) * | 2015-05-01 | 2016-11-10 | Civitas Therapeutics, Inc. | Zolmitriptan powders for pulmonary delivery |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
CA2991108A1 (en) | 2015-07-02 | 2017-01-05 | Civitas Therapeutics, Inc. | Triptan powders for pulmonary delivery |
AR105284A1 (es) | 2015-07-10 | 2017-09-20 | Sanofi Sa | Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón |
GB201709459D0 (en) * | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
US11135379B2 (en) | 2019-02-15 | 2021-10-05 | Bn Intellectual Properties, Inc. | Method of delivering pharmaceutical products |
US11364225B2 (en) * | 2019-08-21 | 2022-06-21 | Bn Intellectual Properties, Inc. | Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6331318B1 (en) | 1994-09-30 | 2001-12-18 | Emisphere Technologies Inc. | Carbon-substituted diketopiperazine delivery systems |
US5352461A (en) | 1992-03-11 | 1994-10-04 | Pharmaceutical Discovery Corporation | Self assembling diketopiperazine drug delivery system |
US6428771B1 (en) | 1995-05-15 | 2002-08-06 | Pharmaceutical Discovery Corporation | Method for drug delivery to the pulmonary system |
GB9827145D0 (en) * | 1998-12-09 | 1999-02-03 | Co Ordinated Drug Dev | Improvements in or relating to powders |
US7305986B1 (en) | 1999-07-23 | 2007-12-11 | Mannkind Corporation | Unit dose capsules for use in a dry powder inhaler |
US7464706B2 (en) | 1999-07-23 | 2008-12-16 | Mannkind Corporation | Unit dose cartridge and dry powder inhaler |
CN1176649C (zh) * | 2002-10-16 | 2004-11-24 | 上海医药工业研究院 | 舒马普坦干粉吸入剂及其制备方法 |
CA2578175C (en) | 2004-08-23 | 2014-10-14 | Mannkind Corporation | Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery |
US7803404B2 (en) | 2005-09-14 | 2010-09-28 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces |
BRPI0707991B8 (pt) * | 2006-02-22 | 2021-05-25 | Mannkind Corp | métodos de preparação de um medicamento em pó seco com uma propriedade farmacêutica melhorada, dito pó seco e uso de uma quantidade efetiva do pó seco |
JP5813323B2 (ja) * | 2007-10-24 | 2015-11-17 | マンカインド コーポレイション | 活性薬剤の送達方法 |
CN101969927A (zh) * | 2007-10-24 | 2011-02-09 | 曼金德公司 | 预防glp-1不良影响的方法 |
CA2728808A1 (en) * | 2008-02-01 | 2009-08-06 | Vectura Limited | Pulmonary formulations of triptans |
EP2570147B1 (en) * | 2008-06-13 | 2017-10-18 | MannKind Corporation | A dry powder inhaler and system for drug delivery |
-
2011
- 2011-11-09 ES ES11788696T patent/ES2732818T3/es active Active
- 2011-11-09 CN CN201710887079.8A patent/CN107854454A/zh active Pending
- 2011-11-09 EP EP19168470.3A patent/EP3536368A1/en active Pending
- 2011-11-09 EP EP11788696.0A patent/EP2637657B1/en active Active
- 2011-11-09 CN CN2011800540606A patent/CN103200940A/zh active Pending
- 2011-11-09 JP JP2013538866A patent/JP6092113B2/ja active Active
- 2011-11-09 BR BR112013011549-1A patent/BR112013011549B1/pt active IP Right Grant
- 2011-11-09 CA CA2817337A patent/CA2817337C/en active Active
- 2011-11-09 MX MX2013005294A patent/MX340112B/es active IP Right Grant
- 2011-11-09 KR KR1020137014686A patent/KR101931392B1/ko active IP Right Grant
- 2011-11-09 WO PCT/US2011/060057 patent/WO2012064892A1/en active Application Filing
- 2011-11-09 AU AU2011326529A patent/AU2011326529B2/en active Active
-
2017
- 2017-02-08 JP JP2017021017A patent/JP6458064B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
KR101931392B1 (ko) | 2018-12-20 |
BR112013011549A2 (pt) | 2017-07-25 |
JP6092113B2 (ja) | 2017-03-08 |
WO2012064892A1 (en) | 2012-05-18 |
CA2817337C (en) | 2020-04-14 |
EP3536368A1 (en) | 2019-09-11 |
AU2011326529B2 (en) | 2015-07-30 |
KR20140008314A (ko) | 2014-01-21 |
EP2637657B1 (en) | 2019-05-22 |
JP2013545748A (ja) | 2013-12-26 |
CN107854454A (zh) | 2018-03-30 |
AU2011326529A1 (en) | 2013-05-02 |
MX340112B (es) | 2016-06-27 |
CA2817337A1 (en) | 2012-05-18 |
JP6458064B2 (ja) | 2019-01-23 |
EP2637657A1 (en) | 2013-09-18 |
CN103200940A (zh) | 2013-07-10 |
BR112013011549B1 (pt) | 2022-01-04 |
JP2017110026A (ja) | 2017-06-22 |
ES2732818T3 (es) | 2019-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2013005294A (es) | Composicion que comprende un agonista de receptor de serotonina y una dicetopiperazina para el tratamiento de migrañas. | |
MX2010004508A (es) | Suministro de agentes activos. | |
IN2014DN03093A (es) | ||
EA200802012A1 (ru) | Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением | |
WO2011014255A8 (en) | Treatment of crohn's disease with laquinimod | |
BRPI1011220A2 (pt) | composição farmacêutica, métodos para tratar uma doença ou distúrbio, para administração respiratória de dois ou mais agentes ativos, para administração respiratória de uma combinação de agentes ativos, e, para preparar uma composição adequada. | |
JP2012041342A5 (es) | ||
MY174727A (en) | Stable, protracted glp-1/glucagon receptor co-agonists for medical use | |
MX2015000538A (es) | Sistemas y metodos de suministro de farmaco en polvo seco. | |
MX352824B (es) | Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación. | |
UA115139C2 (uk) | Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту | |
EA201490149A1 (ru) | Композиция и лекарственное средство, содержащие рекомбинантную человеческую идуронат-2-сульфатазу, и способ их получения | |
IN2015DN04175A (es) | ||
MX2019003173A (es) | Terapia de combinacion con agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada. | |
EA032951B1 (ru) | Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения | |
MX359119B (es) | Formulaciones de liberación sostenida para el suministro de proteínas al ojo y métodos para prepararlas. | |
MD4369B1 (ro) | Utilizarea glicopirolatului pentru tratarea tahicardiei, doză unică, dispozitiv de administrare, metodă de tratament şi profilaxie a tahicardiei | |
WO2010151565A3 (en) | Combination therapies for the treatment of obesity | |
NZ600583A (en) | Visfatin therapeutic agents for the treatment of acne and other conditions | |
MX367070B (es) | Sistemas de administracion de farmaco y metodos para el tratamiento de la prostata. | |
NZ630040A (en) | Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections | |
EA200802350A3 (ru) | Система доставки лекарств | |
RU2017124487A (ru) | НОВЫЙ ПЕПТИД-ИНГИБИТОР PI3Kγ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ ОРГАНОВ ДЫХАНИЯ | |
EA201290278A1 (ru) | Способ лечения сердечной недостаточности с использованием стресскопинподобных пептидов | |
BR112012014107B8 (pt) | sistema terapêutico transdérmico (tts) e processo de produção de tts |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |